top of page

Spark Therapeutics enters into definitive merger agreement with Roche

Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion. Spark Therapeutics will continue its operations in Philadelphia as an independent company within the Roche Group Transaction expected to close in Q2, 2019.

Read more at the company website.

bottom of page